ArticleScientific reports2026
The oncogenic effect and mechanism of LINC00520/miR-372/SLC7A11 axis in renal clear cell carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the expression, function, and potential mechanism of long non-coding RNA LINC00520 as a competitive endogenous RNA in clear cell renal cell carcinoma (ccRCC) by regulating the miR-372/SLC7A11 axis in renal cell carcinoma progression. The expression profiles of LINC00520 and SLC7A11 in various cancers were analyzed using the TCGA database. Using renal cell carcinoma cell lines, the interactions between LINC00520, miR-372, and SLC7A11 were validated through qRT-PCR, Western blot, RNA immunoprecipitation (RIP), and dual-luciferase reporter assays. The effects of LINC00520 on the cell cycle, apoptosis, migration, invasion, and proliferation of renal cancer cells were evaluated using techniques such as flow cytometry, Transwell assay, and immunofluorescence staining. The involvement of miR-372 was validated through functional rescue experiments. Result: LINC00520 and SLC7A11 showed high expression in various cancers (including ccRCC), and their expression levels in ccRCC were positively correlated with tumor staging and grading. Mechanistically, LINC00520 acts as a ceRNA by directly binding to miR-372, relieving its inhibition of the target gene SLC7A11 and upregulating its expression. Functionally, overexpression of LINC00520 can promote the cell cycle progression, migration, invasion, proliferation, and inhibit apoptosis of renal cancer cells, which can be partially reversed by miR-372 mimetics. On the contrary, knocking down LINC00520 produces the opposite phenotype, and this effect can be partially rescued by miR-372 inhibitors. In addition, LINC00520 can downregulate the expression of the tumor suppressor gene P53. LINC00520 plays a pro-cancer role in renal cell carcinoma by adsorbing miR-372 through ceRNA, thereby releasing the inhibition of SLC7A11 by miR-372 and ultimately promoting tumor malignant progression. The LINC00520/miR-372/SLC7A11 axis is a potential prognostic biomarker and therapeutic target for renal cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.